81 related articles for article (PubMed ID: 25857136)
1. [Clinicopathologic characteristics of pancreatic neuroendocrine neoplasm].
Okuwaki K; Kida M; Imaizumi H; Yamauchi H; Koizumi W
Nihon Rinsho; 2015 Mar; 73 Suppl 3():788-91. PubMed ID: 25857136
[No Abstract] [Full Text] [Related]
2. Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors.
Hasegawa T; Yamao K; Hijioka S; Bhatia V; Mizuno N; Hara K; Imaoka H; Niwa Y; Tajika M; Kondo S; Tanaka T; Shimizu Y; Kinoshita T; Kohsaki T; Nishimori I; Iwasaki S; Saibara T; Hosoda W; Yatabe Y
Endoscopy; 2014 Jan; 46(1):32-8. PubMed ID: 24218309
[TBL] [Abstract][Full Text] [Related]
3. [Diagnosis, histopathologic grading and prognostic moleculer marker analysis in patients with pancreatic neuroendocrine neoplasm].
Bao F; Chen GR; Hui P; Cai GP
Zhonghua Bing Li Xue Za Zhi; 2013 Jun; 42(6):426-32. PubMed ID: 24060085
[No Abstract] [Full Text] [Related]
4. Somatostatin receptor 2 and 5 expressions in gastroenteropancreatic neuroendocrine tumors in Turkey.
Yerci O; Sehitoglu I; Ugras N; Cubukcu E; Yuce S; Bedir R; Cure E
Asian Pac J Cancer Prev; 2015; 16(10):4377-81. PubMed ID: 26028102
[TBL] [Abstract][Full Text] [Related]
5. Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study.
Larghi A; Capurso G; Carnuccio A; Ricci R; Alfieri S; Galasso D; Lugli F; Bianchi A; Panzuto F; De Marinis L; Falconi M; Delle Fave G; Doglietto GB; Costamagna G; Rindi G
Gastrointest Endosc; 2012 Sep; 76(3):570-7. PubMed ID: 22898415
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.
Farrell JM; Pang JC; Kim GE; Tabatabai ZL
Cancer Cytopathol; 2014 Oct; 122(10):770-8. PubMed ID: 25044931
[TBL] [Abstract][Full Text] [Related]
7. [Gastrointestinal and pancreatic neuroendocrine tumors: a clinicopathologic and immunohistochemical study].
Sun LM; Qiu XS; Wang EH
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):696-7. PubMed ID: 23302313
[No Abstract] [Full Text] [Related]
8. Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy.
Kaemmerer D; Träger T; Hoffmeister M; Sipos B; Hommann M; Sänger J; Schulz S; Lupp A
Oncotarget; 2015 Sep; 6(29):27566-79. PubMed ID: 26259237
[TBL] [Abstract][Full Text] [Related]
9. [Imaging of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors].
Mure A; Lebtahi R; de Labriolle-Vaylet C; Askienazy S
Gastroenterol Clin Biol; 1998 Oct; 22(10):809-18. PubMed ID: 9854206
[No Abstract] [Full Text] [Related]
10. Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices.
Remes SM; Tuominen VJ; Helin H; Isola J; Arola J
Am J Surg Pathol; 2012 Sep; 36(9):1359-63. PubMed ID: 22895268
[TBL] [Abstract][Full Text] [Related]
11. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods.
Tang LH; Gonen M; Hedvat C; Modlin IM; Klimstra DS
Am J Surg Pathol; 2012 Dec; 36(12):1761-70. PubMed ID: 23026928
[TBL] [Abstract][Full Text] [Related]
12. Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria.
Ozkara S; Aker F; Yesil A; Senates E; Canbey C; Yitik A; Gonen C
Hepatogastroenterology; 2013 Oct; 60(127):1665-72. PubMed ID: 24627925
[TBL] [Abstract][Full Text] [Related]
13. [WHO classification of pancreatic neuroendocrine tumor: overview].
Sasano H; Yazdani S; Kasajima A
Nihon Rinsho; 2015 Mar; 73 Suppl 3():321-6. PubMed ID: 25857041
[No Abstract] [Full Text] [Related]
14. Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes.
Okuwaki K; Kida M; Mikami T; Yamauchi H; Imaizumi H; Miyazawa S; Iwai T; Takezawa M; Saegusa M; Watanabe M; Koizumi W
Cancer; 2013 Dec; 119(23):4094-102. PubMed ID: 24022344
[TBL] [Abstract][Full Text] [Related]
15. [Chinese pathologic consensus for standard diagnosis of gastrointestinal and pancreatic neuroendocrine neoplasm].
Chinese Pathologic Consensus Group for Gastrointestinal and Pancreatic Neuroendocrine Neoplasm
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):257-62. PubMed ID: 21616002
[No Abstract] [Full Text] [Related]
16. Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors.
Boyar Cetinkaya R; Vatn M; Aabakken L; Bergestuen DS; Thiis-Evensen E
Scand J Gastroenterol; 2014 Jun; 49(6):734-41. PubMed ID: 24679166
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Three Ki-67 Index Quantification Methods and Clinical Significance in Pancreatic Neuroendocrine Tumors.
Kroneman TN; Voss JS; Lohse CM; Wu TT; Smyrk TC; Zhang L
Endocr Pathol; 2015 Sep; 26(3):255-62. PubMed ID: 26072124
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors.
Mehta S; de Reuver PR; Gill P; Andrici J; D'Urso L; Mittal A; Pavlakis N; Clarke S; Samra JS; Gill AJ
Medicine (Baltimore); 2015 Oct; 94(40):e1281. PubMed ID: 26447992
[TBL] [Abstract][Full Text] [Related]
19. ASO Author Reflections: Pancreatic Neuroendocrine Tumor Recurrence and Survival Predicted by Ki67.
Nieveen van Dijkum EJM
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):531-532. PubMed ID: 30519760
[No Abstract] [Full Text] [Related]
20. [Neuroendocrine tumors of pancreas (clinicomorphological, immunohistochemical and electron microscopic study)].
Kazantseva IA; Gurevich LE; Kalinin AP; Borodataia EV; Kuzin NM; Egorov AV; Bronshteĭn MI
Arkh Patol; 1999; 61(6):32-8. PubMed ID: 10664818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
